A randomized trial on the optimization of 18F-FDG myocardial uptake suppression: implications for vulnerable coronary plaque imaging.
(2014) The Journal of Nuclear Medicine — Vol. 55, n° 10, p. 1629-1635 (2014)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- (18)F-FDG PET/CT can be used to detect arterial atherosclerotic plaque inflammation. However, avid myocardial glucose uptake may preclude its use for visualizing coronary plaques. Fatty acid loading or calcium channel blockers could decrease myocardial (18)F-FDG uptake, thus assisting coronary plaque inflammation identification. The present prospective randomized trial compared the efficacies of different interventions for suppressing myocardial (18)F-FDG uptake. We also investigated whether circulating free fatty acid (cFFA) levels predicted the magnitude of myocardial (18)F-FDG uptake.
- Affiliations
Citations
Demeure, F., Hanin, F.-X., Bol, A., Vincent, M.-F., Pouleur, A.-C., Gerber, B., Pasquet, A., Jamar, F., Vanoverschelde, J.-L., & Vancraeynest, D. (2014). A randomized trial on the optimization of 18F-FDG myocardial uptake suppression: implications for vulnerable coronary plaque imaging. The Journal of Nuclear Medicine, 55(10), 1629-1635. https://doi.org/10.2967/jnumed.114.138594 (Original work published 2014)